Paraneoplastic neurological disorders

Expert Review of Neurotherapeutics

Volumn 10, Issue 10, 2010, Pages 1559-1568

  Blaes, Franz ^a   Tschernatsch, Marlene ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

antineuronal; autoantibodies; paraneoplastic neurological disorder; pathophysiology; treatment; tumor immunology

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; IMMUNOGLOBULIN;

CLINICAL FEATURE; HUMAN; IMMUNOGENICITY; LUNG CANCER; LUNG SMALL CELL CANCER; NEUROMUSCULAR JUNCTION DISORDER; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PATHOPHYSIOLOGY; PLASMAPHERESIS; REVIEW;

AUTOANTIBODIES; CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; PARANEOPLASTIC POLYNEUROPATHY; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 77957996882     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.134     Document Type: Review

References (111)

1. Dalmau J, Graus F. Paraneoplastic syndromes of the nervous system. In: Cancer of the Nervous System. Loeffler JS (Ed.). Blackwell Scietific Publications, Oxford, UK, 674-700 (1997).
2. Heidenreich F, Schober R, Brinck U, Hartung HP. Multiple paraneoplastic syndromes in a patient with antibodies to neuronal nucleoproteins (anti-Hu). J. Neurol. 242(4), 210-216 (1995).
3. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111(Pt 3), 577-596 (1988).
4. Graus F, DelattreJY, Antoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol Neurosurg. Psychiatry 75(8), 1135-1140 (2004).
5. Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr. Opin. Pharmacol. 9(3), 336-340 (2009).
6. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 147(1), 35-42 (1997).
7. Isaacs H. A syndrome of continuous muscle-fibre activity. J. Neurol. Neurosurg. Psychiatry 24, 319-325 (1961).
8. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. Autoimmune etiology for acquired neuromyotonia. Lancet 338, 75-77 (1991). First demonstration of autoimmunity in the etiology of neuromyotonia.
9. Partanen VSJ, Soininen H, Saksa M, Riekkinen P. Electromyographic and nerve conduction findings in a patient with neuromyotonia, normcalcemic tetany and small cell lung cancer. Acta Neurol. Scand. 61, 216-226 (1980).
10. Evoli A, Lo Monaco M, Marra R, Lino MM, Batocchi AP, Tonali PA. Multiple paraneoplastic diseases associated with thymoma. Neuromuscul. Disord. 9(8), 601-603 (1999).
11. Lahrmann H, Albrecht G, Drlicek M et al. Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle Nerve 24(6), 834-838 (2001).
12. Voltz RD, Albrich WC, Nagele A et al. Paraneoplastic myasthenia gravis: Detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 49(5), 1454-1457 (1997).
13. Yamamoto AM, Gajdos P, Eymard B et al. Anti-titin antibodies in myasthenia gravis. Arch. Neurol. 58(6), 885-890 (2001).
14. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 57(9), 1579-1582 (2001).
15. Vural B, Chen LC, Saip P et al. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 103(12), 2575-2583 (2005).
16. Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70(12), 924-928 (2008). Important study demonstrating that the SOX-1 antibody is a marker for paraneoplastic Lambert-Eaton myasthenic syndrome.
17. Titulaer MJ, Klooster R, Potman M et al. SOX antibodies in small cell lung cancer and Lambert-Eaton myasthenic syndrome: Frequency and relation with survival. J. Clin. Oncol. 27(26), 4260-4267 (2009).
18. Vincent A. Immunology of acetylcholine receptors in relation to myasthenia gravis. Physiol. Rev. 60(3), 756-824 (1980).
19. Vincent A, Jacobson L, Plested P et al. Antibodies affecting ion channel function in acquired neuromyotonia, in seropositive and seronegative myasthenia gravis, and in antibody-mediated arthrogryposis multiplex congenita. Ann. NY Acad. Sci. 841, 482-496 (1998).
20. 2+ flux in a human small cell carcinoma cell line. Nature 317(6039), 737-739 (1985).
21. Lang B, Newsom-Davis J, Wray D, Murray N. Autoimmune etiology for myasthenic (Eaton-Lambert) syndrome. Lancet 2(8240), 224 (1981).
22. Venuta F, Rendina EA, De Giacomo T et al. Thymectomy for myasthenia gravis: A 27-year experience. Eur. J. Cardiothorac. Surg. 15(5), 621-624 (1999).
23. Toyka KV. Myasthenia gravis. In: Current Therapy in Neurologic Diseases III. Johnson RT (Ed.). BC Decker, PA, USA, 385-391 (1990).
24. Gajdos PH, Chevret S, Clair B, Tranchant C, Chastang C. Clinical-trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann. Neurol. 41(6), 789-796 (1997).
25. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med. 321, 1567-1571 (1989).
26. Chalk CH, Murray NM, Newsom-Davis J et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 40(10), 1552-1556 (1990).
27. Sanders DB. Lambert-Eaton myasthenic syndrome: Clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann. Neurol. 37(Suppl. 1), S63-S73 (1995).
28. Newsom-Davis J, Murray N, Wray D et al. Lambert-Eaton myasthenic syndrome: Electrophysiological evidence for a humoral factor. Muscle Nerve 5(9S), S17-S20 (1982).
29. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in Lambert-Eaton myasthenic syndrome. Neurology 34(4), 480-485 (1984).
30. Bain PG, Motomura M, Newsom-Davis J et al. Effect of intravenous immunoglobulin (IvIg) treatment on muscle weakness and calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47(3), 678-683 (1996).
31. Newsom-Davis J, Mills K. Immunological associations of acquired neuromyotonia (Isaacs'syndrome). Report of five cases and literature review. Brain 116(Pt 2), 453-469 (1993).
32. Hayat GR, Kulkantrakorn K, Campbell WW, Giuliani MJ. Neuromyotonia: Autoimmune pathogenesis and response to immune modulating therapy. J. Neurol. Sci. 181(1-2), 38-43 (2000).
33. Graus F, Delattre JY, Antoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry 75(8), 1135-1140 (2004).
34. Camdessanché JP, Antoine JC, Honnorat J et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 125(Pt 1), 166-175 (2002).
35. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N. Engl. J. Med. 343(12), 847-855 (2000).
36. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 7(4), 327-340 (2008).
37. Sabater L, Bataller L, Carpentier AF et al. Protein kinase C g autoimmunity in paraneoplastic cerebellar degeneration and nonsmall-cell lung cancer. J. Neurol. Neurosurg. Psychiatry 77, 1359-1362 (2006).
38. Sillevis Smitt P, Kinoshita A, De Leeuw B et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N. Engl. J. Med. 342(1), 21-27 (2000).
39. Luque FA, Furneaux HM, Ferziger R et al. Anti-Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer. Ann. Neurol. 29(3), 241-251 (1991).
40. Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann. Neurol. 53(3), 347-353 (2003).
41. Didelot A, Honnorat J. Update on paraneoplastic neurological syndromes. Curr. Opin. Oncol. 21(6), 566-572 (2009).
42. Dalmau J, Gleichman AJ, Hughes EG et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol. 7(12), 1091-1098 (2008). Description of the NMDA receptor as a new antigen associated with a special limbic encephalitis phenotype.
43. Vincent A, Buckley C, Schott JM et al. Potassium channel antibody-asociated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis. Brain 127(Pt 3), 701-712 (2004).
44. Ances BM, Vitaliani R, Taylor RA et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128(Pt 8), 1764-1777 (2005).
45. Lai M, Hughes EG, Peng X et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann. Neurol. 65(4), 424-434 (2009).
46. De Camilli P, Thomas A, Cofiell R et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-man syndrome with breast cancer. J. Exp. Med. 178(6), 2219-2223 (1993). (Pubitemid 23344881)
47. Vernino S, Tuite P, Adler CH et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann. Neurol. 51(5), 625-630 (2002).
48. Honnorat J, Cartalat-Carel S, Ricard D et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J. Neurol. Neurosurg. Psychiatry 80(4), 412-416 (2009).
49. Cross SA, Salomao DR, Parisi JE et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann. Neurol. 54(1), 38-50 (2003).
50. Graus F, Dalmau J, Valldeoriola F et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J. Neuroimmunol. 74(1-2), 55-61 (1997).
51. Vedeler CA, Antoine JC, Giometto B et al. Management of paraneoplastic neurological syndromes: Report on an ENS task force. Eur. J. Neurol. 13(7), 682-690 (2006).
52. Younes-Mhenni S, Janier MF, Cinotti L et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127(10), 2331-2338 (2004).
53. Graus F, Vega F, Delattre JY et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies. Neurology 42(3 Pt 1), 536-540 (1992).
54. Graus F, Keime-Guibert F, Rene R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain 124(Pt 6), 1138-1148 (2001). Largest series of anti-Hu patients with the exact description of prognostic factors and outcome in anti-Hu-positive patients.
55. Blaes F, Strittmatter M, Merkelbach S et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J. Neurol. 246(4), 299-303 (1999).
56. Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma-associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J. Neurol. Neurosurg. Psychiatry 67, 7-14 (1999).
57. Tschernatsch M, Stolz E, Strittmatter M, Kaps M, Blaes F. Antinuclear antibodies define a subgroup of paraneoplastic neuropathies - clinical and immunological data. J. Neurol. Neurosurg. Psychiatry 76(12), 1702-1706 (2005).
58. Dalmau J, Graus F, Villarejo A et al. Clinical analysis of anti-Mα2-associated encephalitis. Brain 127(Pt 8), 1831-1844 (2004).
59. Elovaara I, Apostolski S, van Doorn P et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol. 15(9), 893-908 (2008).
60. Wilkinson PC. Serologic findings in carcinomatous neuromyopathy. Lancet 1, 1301-1303 (1964).
61. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am. J. Pathol. 141(4), 881-886 (1992).
62. Anderson NE, Budde-Steffen C, Rosenblum MK et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: A distinct paraneoplastic syndrome. Medicine 67(2), 100-109 (1988).
63. Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein NOVA-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc. Natl. Acad. Sci. USA 95(22), 13254-13259 (1998).
64. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. Ann. Neurol. 53(5), 580-587 (2003).
65. Dalmau J, Gultekin SH, Voltz R et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 122, 27-39 (1999).
66. Voltz R, Gultekin SH, Rosenfeld M et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N. Engl. J. Med. 340, 1788-1795 (1999).
67. Rosenfeld M, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann. Neurol. 50, 339-348 (2001).
68. Jaeckle KA, Graus F, Houghton A, Cardon-Cardo C, Nielsen SL, Posner JB. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann. Neurol. 18(5), 592-600 (1985).
69. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry 61(3), 270-278 (1996).
70. Antoine JC, Honnorat J, Camdessanche JP et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann. Neurol. 49(2), 214-221 (2001).
71. Honnorat J, Byk T, Kusters I et al. Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. Eur. J. Neurosci. 11(12), 4226-4232 (1999). (Pubitemid 30009253)
72. Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G; PND Euronetwork. Paraneoplastic neurologic syndrome in the PND Euronetwork database: A European study from 20 centers. Arch. Neurol. 67(3), 330-335 (2010).
73. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): Marker of lung cancer-related neurological autoimmunity. Ann. Neurol. 47, 297-305 (2000).
74. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: Marker of lung cancer-related autoimmunity. Ann. Neurol. 50, 301-311 (2001).
75. Tschernatsch M, Klotz M, Probst C et al. Synaptophysin is an autoantigen in paraneoplastic neuropathy. J. Neuroimmunol. 197(1), 81-86 (2008).
76. Dropcho EJ. Antiamphiphysin antibodies with small cell lung carcinoma and paraneoplastic encephalomyelitis. Ann. Neurol. 39(5), 659-667 (1996).
77. Sommer C, Weishaupt A, Brinkhoff J et al. Paraneoplastic stiff-person syndrome: Passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365(9468), 1406-1411 (2005). First successful passive transfer model of a defined antineuronal antibody in rats, causing stiff-man syndrome in these animals.
78. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun. Rev. 8(5), 410-414 (2009).
79. Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest. Ophthalmol. Vis. Sci. 38(2), 283-291 (1997). First study showing autoantibody-induced apoptosis in paraneoplastic neuro-ophthalmological syndromes.
80. Kimpinski K, Iodice V, Vernino S, Sandroni P, Low PA. Association of N-type calcium channel autoimmunity in patients with autoimmune autonomic ganlgionopathy. Auton. Neurosci. 150(1-2), 136-139 (2009).
81. Buckley C, Oger J, Clover L et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann. Neurol. 50(1), 73-78 (2001).
82. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 70(20), 1883-1890 (2008).
83. Irani SR, Bera K, Waters P et al. N-methyl-d-aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 13(Pt 6), 1655-1667 (2010).
84. Lancaster E, Lai M, Peng X et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: Case series and characterisation of the antigen. Lancet Neurol. 9(1), 67-76 (2010).
85. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202(4), 473-477 (2005). Identification of aquaporin-4 as the target antigen in neuromyelitis optica.
86. Pittock SJ, Lennon VA. Aquaporin-4 antibodies in a paraneoplastic context. Arch. Neurol. 65(5), 629-632 (2008).
87. Verschuuren JJ, Dalmau J, Hoard R, Posner JB. Paraneoplastic anti-Hu serum: Studies on human tumor cell lines. J. Neuroimmunol. 79(2), 202-210 (1997).
88. Schäfer KH, Klotz M, Mergner D, Mestres P, Schimrigk K, Blaes F. IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J. Autoimmun. 15(4), 479-484 (2000).
89. Greenlee JE, Parks, TN, Jaeckle KA. Type IIa (anti-Hu) antineuronal antibodies produce destruction of rat cerebellar granule neurones in vitro. Neurology 43(10), 2049-2054 (1993).
90. Tanaka M, Tanaka K, Onodera O, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. Clin. Neurol. Neurosurg. 97(1), 95-100 (1995).
91. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4(11), 1321-1324 (1998). Demonstration of tumor-specific T cells and an effective anti-tumor immunity in patients with paraneoplastic cerebellar degeneration.
92. Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 51(4), 1146-1150 (1998).
93. + T T cells. J. Clin. Invest. 119(7), 2042-2051 (2009).
94. Pellkofer H, Schubart AS, Höftberger R et al. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain 127(Pt 8), 1822-1830 (2004). Passive transfer of Ma-reactive T cells inducing encephalitis.
95. Kazarian M, Calbo J, Proost N, Carpenter CL, Berns A, Laird-Offringa IA. Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J. Neuroimmunol. 217(1-2), 38-45 (2009). Description of anti-Hu antibody production in animals with spontaneous developing small-cell lung cancer.
96. Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - a quantitative Western Blot analysis. Ann. Neurol. 27(5), 544-552 (1990).
97. Graus F, Dalmau J, Rene R et al. Anti-Hu antibodies in patients with small cell lung cancer: Association with complete response to therapy and improved survival. J. Clin. Oncol. 15(8), 2866-2872 (1997).
98. Blaes F, Klotz M, Huwer H et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann. Thorac. Surg. 69(1), 254-258 (2000).
99. Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer 37(6), 846-852 (1976).
100. Dalmau J, Graus F, Cheung NK et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 75(1), 99-109 (1995).
101. Cohn SL, Salwen H, Herst CV et al. Single copies of the n-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus-myoclonus. Cancer 62(5), 723-726 (1988).
102. Hahn A, Claviez A, Brinkmann G, Altermatt HJ, Schneppenheim R, Stephani U. Paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. Neuropediatrics 31(1), 42-44 (2000).
103. Blaes F, Lang B. Opsoclonus-myoclonus syndrome in childhood. In: Autoantibodies in Neurological Diseases. Vincent A, Martino G (Eds). Springer, Milan, Italy, 144-151 (2001).
104. Korfei M, Fühlhuber V, Schmidt-Wöll T et al. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus syndrome. J. Neuroimmunol. 170(1-2), 150-157 (2005).
105. Blaes F, Fühlhuber V, Korfei M et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann. Neurol. 58(2), 313-317 (2005).
106. Sabater L, Xifro X, Saiz A, Alberch J, Graus F. Analysis of autoantibodies to neuronal surface antigens in adult opsoclonus myoclonus. J. Neuroimmunol. 196(1-2), 188-191 (2008).
107. Fühlhuber V, Bick S, Kirsten A et al. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J. Neuroimmunol. 210(1-2), 87-91 (2009).
108. Pranzatelli MR, Tate ED, Travelstead AL et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J. Pediatr. Hematol. Oncol. 28(9), 585-593 (2006).
109. Russo C, Cohn SL, Petruzzi MJ, Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the pediatric oncology group. Med. Pediatr. Oncol. 28(4), 284-288 (1997).
110. Vernino S. Neuronal acetylcholine receptor autoimmunity. Ann. NY Acad. Sci. 1132, 124-128 (2008).
111. McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetylcholine receptor autoantibody. Arch. Neurol. 66(6), 735-741 (2009).